AbbVie initiates trial for telisotuzumab adizutecan in mCRC with FOLFOX and bevacizumab/panitumumab
A new study is evaluating the efficacy and safety of telisotuzumab adizutecan in combination with standard mCRC treatments.
Therapeutic Area
Therapeutic area intelligence for mCRC with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.